Literature DB >> 19890631

Reduced parahippocampal and lateral temporal GABAA-[11C]flumazenil binding in major depression: preliminary results.

Ursula M H Klumpers1, Dick J Veltman, Madeleine L Drent, Ronald Boellaard, Emile F I Comans, Gerben Meynen, Adriaan A Lammertsma, Witte J G Hoogendijk.   

Abstract

PURPOSE: Major depressive disorder (MDD) has been related to both a dysfunctional gamma-amino butyric acid (GABA) system and to hyperactivity of the hypothalamic-pituitary-adrenal axis (HPA). Although GABA has been suggested to inhibit HPA axis activity, their relationship has never been studied at the level of the central GABA(A)-benzodiazepine receptor in depressed patients or in relation to antidepressant treatment.
METHODS: Eleven depressed outpatients were compared, before and after treatment with citalopram, with nine age-matched healthy controls. The subjects were scanned using the positron emission tomography (PET) tracer [(11)C]flumazenil ([(11)C]FMZ). Parametric voxel-by-voxel Logan plots were compared with methods based on regions of interest (ROI), to provide volume of distribution (V(T)) and binding potential (BP(ND)) values. Plasma GABA levels were determined and a dexamethasone-corticotropin releasing hormone (DEX-CRH) test was performed.
RESULTS: In MDD, parametric voxel-by-voxel Logan plots showed bilateral reduced [(11)C]FMZ binding in the parahippocampal gyrus and right lateral superior temporal gyrus (p uncorrected < or =0.001). In the temporal area, [(11)C]FMZ binding showed a strong inverse correlation with HPA axis activity. Plasma GABA did not discriminate MDD from controls, but correlated inversely with [(11)C]FMZ binding in the right insula. Following treatment with citalopram, voxel-based analysis revealed reduced binding in the right lateral temporal gyrus and dorsolateral prefrontal cortex.
CONCLUSION: The bilateral reduction in limbic parahippocampal and right temporal [(11)C]FMZ binding found in MDD indicates decreased GABA(A)-benzodiazepine receptor complex affinity and/or number. The inverse relationship between GABA(A) binding in the temporal lobe and HPA axis activity, suggests that HPA axis hyperactivity is partly due to reduced GABA-ergic inhibition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19890631     DOI: 10.1007/s00259-009-1292-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  57 in total

1.  Combined method for the determination of gamma-aminobutyric and beta-alanine in cerebrospinal fluid by stable isotope dilution mass spectrometry.

Authors:  E A Struys; W S Guérand; H J ten Brink; C Jakobs
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-09-10

2.  Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine.

Authors:  W J Inder; T C Prickett; R T Mulder; R A Donald; P R Joyce
Journal:  Psychopharmacology (Berl)       Date:  2001-06       Impact factor: 4.530

Review 3.  Nonparametric analysis of statistic images from functional mapping experiments.

Authors:  A P Holmes; R C Blair; J D Watson; I Ford
Journal:  J Cereb Blood Flow Metab       Date:  1996-01       Impact factor: 6.200

4.  Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects.

Authors:  J Logan; J S Fowler; N D Volkow; A P Wolf; S L Dewey; D J Schlyer; R R MacGregor; R Hitzemann; B Bendriem; S J Gatley
Journal:  J Cereb Blood Flow Metab       Date:  1990-09       Impact factor: 6.200

5.  SPECT and neuropsychological performance in severe depression treated with ECT.

Authors:  E Mervaala; M Könönen; J Föhr; M Husso-Saastamoinen; M Valkonen-Korhonen; J T Kuikka; H Viinamäki; A K Tammi; J Tiihonen; J Partanen; J Lehtonen
Journal:  J Affect Disord       Date:  2001-09       Impact factor: 4.839

6.  Increased cortical GABA concentrations in depressed patients receiving ECT.

Authors:  Gerard Sanacora; Graeme F Mason; Douglas L Rothman; Fahmeed Hyder; James J Ciarcia; Robert B Ostroff; Robert M Berman; John H Krystal
Journal:  Am J Psychiatry       Date:  2003-03       Impact factor: 18.112

7.  The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders.

Authors:  I Heuser; A Yassouridis; F Holsboer
Journal:  J Psychiatr Res       Date:  1994 Jul-Aug       Impact factor: 4.791

8.  GABA levels in CSF of patients with psychiatric disorders.

Authors:  B I Gold; M B Bowers; R H Roth; D W Sweeney
Journal:  Am J Psychiatry       Date:  1980-03       Impact factor: 18.112

9.  Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography.

Authors:  Gregor Hasler; Allison C Nugent; Paul J Carlson; Richard E Carson; Marilla Geraci; Wayne C Drevets
Journal:  Arch Gen Psychiatry       Date:  2008-10

10.  Brain GABAA/benzodiazepine binding sites and glutamic acid decarboxylase activity in depressed suicide victims.

Authors:  S C Cheetham; M R Crompton; C L Katona; S J Parker; R W Horton
Journal:  Brain Res       Date:  1988-09-13       Impact factor: 3.252

View more
  29 in total

1.  The role of GABA in primary insomnia.

Authors:  David T Plante; J Eric Jensen; John W Winkelman
Journal:  Sleep       Date:  2012-06-01       Impact factor: 5.849

2.  Reduced γ-aminobutyric acid in occipital and anterior cingulate cortices in primary insomnia: a link to major depressive disorder?

Authors:  David T Plante; J Eric Jensen; Laura Schoerning; John W Winkelman
Journal:  Neuropsychopharmacology       Date:  2012-02-08       Impact factor: 7.853

3.  GABAergic control of depression-related brain states.

Authors:  Bernhard Luscher; Thomas Fuchs
Journal:  Adv Pharmacol       Date:  2015-01-14

Review 4.  Molecular imaging in patients with mood disorders: a review of PET findings.

Authors:  Qiaozhen Chen; Weibo Liu; Huichun Li; Hong Zhang; Mei Tian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

Review 5.  Convergent Mechanisms Underlying Rapid Antidepressant Action.

Authors:  Panos Zanos; Scott M Thompson; Ronald S Duman; Carlos A Zarate; Todd D Gould
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

6.  AnkG hemizygous mice present cognitive impairment and elevated anxiety/depressive-like traits associated with decreased expression of GABA receptors and postsynaptic density protein.

Authors:  Cui Liu; Ling Zhang; Jie Wu; Xiaolong Sui; Yanfeng Xu; Lan Huang; Yunlin Han; Hua Zhu; Yanhong Li; Xiuping Sun; Chuan Qin
Journal:  Exp Brain Res       Date:  2017-08-18       Impact factor: 1.972

7.  Human biodistribution and dosimetry of the PET radioligand [¹¹C]flumazenil (FMZ).

Authors:  Charles M Laymon; Rajesh Narendran; Neale S Mason; Jonathan P Carney; Brian J Lopresti; Chester A Mathis; James M Mountz; Donald Sashin; W Gordan Frankle
Journal:  Mol Imaging Biol       Date:  2012-02       Impact factor: 3.488

8.  Prefrontal Cortex GABAergic Deficits and Circuit Dysfunction in the Pathophysiology and Treatment of Chronic Stress and Depression.

Authors:  Sriparna Ghosal; Brendan Hare; Ronald S Duman
Journal:  Curr Opin Behav Sci       Date:  2017-04

9.  CRH receptor antagonism reverses the effect of social subordination upon central GABAA receptor binding in estradiol-treated ovariectomized female rhesus monkeys.

Authors:  V Michopoulos; M Embree; K Reding; M M Sanchez; D Toufexis; J R Votaw; R J Voll; M M Goodman; J Rivier; M E Wilson; S L Berga
Journal:  Neuroscience       Date:  2013-07-12       Impact factor: 3.590

10.  Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment.

Authors:  Zhen Ren; Horia Pribiag; Sarah J Jefferson; Matthew Shorey; Thomas Fuchs; David Stellwagen; Bernhard Luscher
Journal:  Biol Psychiatry       Date:  2016-02-13       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.